News

Begins the exchange program between IDIBELL and SZBL

It begins the selection of candidates to carry out a doctoral program in Regenerative Medicine between the SZBL and the IDIBELL. The program will run mainly at SZBL and will have a minimum six months stay at IDIBELL.

Leer más about Begins the exchange program between IDIBELL and SZBL

SARS-CoV-2 vaccines are safe and effective in people with immunodeficiency

The analysis show that these vaccines are safe and able to generate immunity in three out of four patients with immune system defects from birth, and in almost all patients treated with immunosuppressants who were evaluated in the study.

Leer más about SARS-CoV-2 vaccines are safe and effective in people with immunodeficiency

A clinical trial shows the safety and potential of an oncolytic virus against advanced pancreatic cancer

Preliminary results show that the virus is active, reaches the primary tumor and metastases, and triggers the immune system response. In addition, at recommended doses, it has no important adverse effects.

Leer más about A clinical trial shows the safety and potential of an oncolytic virus against advanced pancreatic cancer

Psychosocial factors determine the effectiveness of self-care in patients with heart failure

Lack of family and social support and depressive symptoms are the main factors that impair patients’ ability to adopt healthy habits and practices.

Leer más about Psychosocial factors determine the effectiveness of self-care in patients with heart failure

The second edition of the project “VacunAcció: how to immunize yourself against misinformation” concludes

The initiative, promoted by the Escolab program and carried out by IDIBELL, has been carried out with 4th year ESO students from the Escola Pia of Granollers.

Leer más about The second edition of the project “VacunAcció: how to immunize yourself against misinformation” concludes

A study presents MCLA-158, the first drug candidate targeting cancer stem cells from solid tumors

An international consortium led by IRB Barcelona and the biotech company Merus, with the participation of IDIBELL and the Catalan Institute of Oncology, presents the preclinical data leading to the discovery of MCLA-158 and its action mechanism on cancer stem cells.

Leer más about A study presents MCLA-158, the first drug candidate targeting cancer stem cells from solid tumors

Two IDIBELL members receive 2021 Biologist Day awards

Two of the 2021 Biologist Day awards, celebrated by the College of Biologists of Catalonia, are given to two members of IDIBELL: Dr. Milagros González Garrigues and Dr. Núria Sala-Serra.

Leer más about Two IDIBELL members receive 2021 Biologist Day awards

Success at the Presentation Conference of the Bellvitge Campus Scientific and Technical Services

On Thursday afternoon, April 21, the Presentation Conference of the Bellvitge Campus Scientific and Technical Services for Clinical Research took place with the aim of raising awareness of the research support services that IDIBELL and UB offer to researchers in the Bellvitge Campus.

Leer más about Success at the Presentation Conference of the Bellvitge Campus Scientific and Technical Services
Scroll to Top